Tazarotene
- Generic Name
- Tazarotene
- Brand Names
- Arazlo, Duobrii, Fabior, Tazorac
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21NO2S
- CAS Number
- 118292-40-3
- Unique Ingredient Identifier
- 81BDR9Y8PS
Overview
Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).
Background
Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).
Indication
Used to treat psoriasis, acne and sun damaged skin (photodamage).
Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis)
- Benign facial lentigines
- Facial fine wrinkling
- Facial hyperpigmentation
- Facial hypopigmentation
- Mild Acne vulgaris
- Moderate Acne vulgaris
Clinical Trials
FDA Approved Products
011312 NIACINAMIDE 4% / TAZAROTENE 0.05%
Manufacturer:Sincerus Florida, LLC
Route:TOPICAL
Strength:0.05 g in 100 g
Approved: 2020/07/02
NDC:72934-2208
Duobrii
Manufacturer:Bausch Health US, LLC
Route:TOPICAL
Strength:0.45 mg in 1 g
Approved: 2020/01/01
NDC:0187-0653
Tazarotene
Manufacturer:Pacific Pharma, Inc.
Route:TOPICAL
Strength:1 mg in 1 g
Approved: 2023/02/03
NDC:60758-561
CLINDAMYCIN 1% / NIACINAMIDE 2% / TAZAROTENE 0.05%
Manufacturer:Sincerus Florida, LLC
Route:TOPICAL
Strength:0.05 g in 100 g
Approved: 2019/05/09
NDC:72934-1050
Tazorac
Manufacturer:Physicians Total Care, Inc.
Route:ORAL
Strength:1 mg in 1 g
Approved: 2010/10/22
NDC:54868-4456
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath